Brief: Viracta Therapeutics Reacquires Exclusive Development And Commercialization Rights For Its All-Oral Combination Therapy In China
23/08/2021 13:09
Aug 23 (Reuters) - Viracta Therapeutics Inc VIRX.O :
* VIRACTA THERAPEUTICS REACQUIRES EXCLUSIVE DEVELOPMENT AND
COMMERCIALIZATION RIGHTS FOR ITS ALL-ORAL COMBINATION THERAPY IN
CHINA
Source text for Eikon: ID:nPn151Zmna
Further company coverage: VIRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Viracta Therapeutics
See all newsBrief: Viracta Therapeutics Announces Wind Down Of Operations
Brief: Viracta Therapeutics Announces Closure Of Naval-1 Clinical Trial And Exploration Of Strategic Alternatives
Brief: Viracta Therapeutics Receives Notice Of Non-Compliance From Nasdaq
Viracta Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Viracta Therapeutics Reports Q3 2024 Financial Results And Provides Business Update